R. K. Elwood

Health state utilities in latent and active tuberculosis.

C. Marra, F. Marra, N. Guo, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Levofloxacin treatment of active tuberculosis and the risk of adverse events.

P. Shi, C. Marra, F. Marra, 2005, Chest.

Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.

A. Brooks-Wilson, V. Cook, K. Richardson, 2009, Pharmacogenomics.

Severe hepatic complications of antituberculous therapy.

R. Elwood, M. O. Turner, Mark O Turner, 1999, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment.

A. Anis, C. Marra, F. Marra, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada

V. Cook, M. Sadatsafavi, F. Marra, 2017, PloS one.